Sanofi India Posts Strong Q2 2026 Results Driven by Diabetes Portfolio Growth and Profitability Gains

Sanofi India Posts Strong Q2 2026 Results Driven by Diabetes Portfolio Growth and Profitability Gains​

Sanofi India Limited announced financial results for the quarter ended June 30, 2026, demonstrating strong performance led by its diabetes portfolio. The company reported domestic net sales growth of 8%, while total net sales grew by 6% compared to the second quarter of 2025.

The quarterly results reflected improved profitability and operational efficiency across the business segments. Profits before tax and exceptional items increased by 19%, reaching INR 112 crores, up from INR 94 crores in Q2 2025. The profit before tax as a percentage of net sales also saw an improvement, rising to 27% in Q2 2026, compared to 24% in Q2 2025.

The company attributed this financial enhancement and improved profitability mix to disciplined cost management through operational efficiencies. Operating expenses (comprising employee costs and other expenses) declined by 5% when compared to the second quarter of 2025.

Key Financial Highlights for Q2 2026​

A summary of the key financial indicators from Sanofi India Limited is provided below:

Growth and Market Leadership in Diabetes Care​

The Insulin portfolio continued its robust trajectory, recording double-digit growth of 14% for the second consecutive quarter. This performance reinforces Sanofi's leadership position in the basal analog market, where it holds a 58% value share and 61% volume share. The growth was significantly driven by Lantus®, Toujeo®, and Apidra®, along with the successful performance of Soliqua®, which is a premium offering in the premix diabetes space.

Furthermore, the public sector business saw an acceleration rate of 70%. This expansion was supported by opening new accounts for Toujeo® and Soliqua® under the CARE Accounts initiative, strengthening Sanofi's presence in the diabetes injectable segment. Strategic partnerships established across Cardiovascular, Oral anti-Diabetes, and Central Nervous System segments continue to build a strong foundation, with partnership revenues showing a 2% growth in Q2 2026.

Management Perspective​

Deepak Arora, Managing Director of Sanofi India, highlighted that Q2 2026 represents purposeful and profitable growth for the company, driven by its diabetes portfolio performance and a 19% increase in PBT. He noted that their acceleration in the public sector demonstrates not just expansion, but broadening access to innovative therapies across the country. Arora stated that with a 57.3% value share in the diabetes injectable segment and a modernized go-to-market model, the foundation for sustainable, long-term value creation is firm.

Governance and Organizational Updates​

The Board of Directors meeting held on August 4, 2026, approved several governance updates. The company also undertook the re-constitution of two key committees effective from October 1, 2026:

• Stakeholders Relationship Committee: Members include Mr. Siraj Chaudhry (Chairman), Mr. Deepak Arora (Member), and Ms. Sudipta Chakraborty (Member).
• Risk Management Committee: The committee comprises Ms. Rajani Kesari (Chairperson), Mr. Siraj Chaudhry, Mr. Deepak Arora, and Mr. Mahadev Gawade.

Additionally, the Board approved that Mr. Rachid Ayari will be deleted from the list of Key Managerial Personnels authorized to determine materiality of an event or information, effective from the close of business hours on September 30, 2026, following his stepping down as Whole Time Director and Chief Financial Officer.

SANOFI Stock Price Movement​

Today, Sanofi India Limited shares edged higher to close at ₹3394.3, marking a 0.39% gain in trading activity. The stock saw a volume of 17,756 shares traded during the session.